[go: up one dir, main page]

EP3672586A1 - Inhibiteurs d'immunoprotéasome et agent immunosuppresseur dans le traitement de troubles auto-immuns - Google Patents

Inhibiteurs d'immunoprotéasome et agent immunosuppresseur dans le traitement de troubles auto-immuns

Info

Publication number
EP3672586A1
EP3672586A1 EP18765279.7A EP18765279A EP3672586A1 EP 3672586 A1 EP3672586 A1 EP 3672586A1 EP 18765279 A EP18765279 A EP 18765279A EP 3672586 A1 EP3672586 A1 EP 3672586A1
Authority
EP
European Patent Office
Prior art keywords
administered
immunosuppressive agent
immunoproteasome inhibitor
immunoproteasome
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18765279.7A
Other languages
German (de)
English (en)
Inventor
Tony Muchamuel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kezar Life Sciences Inc
Original Assignee
Kezar Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kezar Life Sciences Inc filed Critical Kezar Life Sciences Inc
Publication of EP3672586A1 publication Critical patent/EP3672586A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Definitions

  • proteasome-mediated degradation In eukaryotes, protein degradation is predominately mediated through the ubiquitin proteasome pathway in which proteins targeted for destruction are ligated to the 76 amino acid polypeptide ubiquitin. Once targeted, ubiquitinated proteins then serve as substrates for the 26S proteasome, a multicatalytic protease, which cleaves proteins into short peptides through the action of its three major proteolytic activities. While having a general function in intracellular protein turnover, proteasome-mediated degradation also plays a key role in many processes such as major histocompatibility complex (MHC) class I antigen
  • the 20S proteasome is a 700 kDa cylindrical-shaped multicatalytic protease complex comprised of 28 subunits organized into four rings. In yeast and other eukaryotes, 7 different a subunits form the outer rings and 7 different ⁇ subunits comprise the inner rings. The a subunits serve as binding sites for the 19S (PA700) and 1 1 S (PA28) regulatory complexes, as well as a physical barrier for the inner proteolytic chamber formed by the two ⁇ subunit rings. Thus, in vivo, the proteasome is believed to exist as a 26S particle ("the 26S proteasome").
  • This family includes, for example, penicillin G acylase (PGA), penicillin V acylase (PVA), glutamine PRPP amidotransferase (GAT), and bacterial glycosylasparaginase.
  • PGA penicillin G acylase
  • PVA penicillin V acylase
  • GAT glutamine PRPP amidotransferase
  • bacterial glycosylasparaginase bacterial glycosylasparaginase.
  • three major proteolytic activities have been defined for the eukaryote 20S proteasome: chymotrypsin- like activity (CT-L), which cleaves after large hydrophobic residues; trypsin-like activity (T-L), which cleaves after basic residues; and peptidylglutamyl peptide hydrolyzing activity (PGPH) or caspase-like (C-L), which cleaves after acidic residues.
  • C-L chymotrypsin- like activity
  • T-L trypsin-
  • autoimmune disease comprising administering to the subject (a) an immunoproteasome inhibitor and (b) an immunosuppressive agent in an amount sufficient to treat the autoimmune disease.
  • the subject is human.
  • the autoimmune disease is lupus nephritis or systemic lupus erythematosus (SLE).
  • the autoimmune disease is systemic vasculitis or an idiopathic inflammatory myopathy.
  • the immunoproteasome inhibitor and the immunosuppressive agent are administered simultaneously, and in some cases, can be co-formulated. In some cases, the immunoproteasome inhibitor and the immunosuppressive agent are administered sequentially (e.g., the immunoproteasome inhibitor before or after the immunosuppressive agent).
  • the efficacy of administering the immunoproteasome inhibitor and the immunosuppressive agent is greater than the efficacy of administering the
  • the efficacy is exhibited by a decrease in proteinuria or urine protein to creatinine ratio compared to either (a) a subject not administered the immunoproteasome inhibitor and the
  • the subject exhibits a decrease in the urine protein to creatinine ratio of at least 50% compared to the urine protein to creatinine ratio of the subject prior to administration of the
  • the subject exhibits a urine protein to creatinine ratio of 0.5 or less after administration of the immunoproteasome inhibitor and the immunosuppressive agent.
  • the immunoproteasome inhibitor has a structure of formula (I): (I) wherein K is CH(O N or CH; R 1 is
  • R 2 is ,
  • the immunoproteasome inhibitor is selected from the immunoproteasome inhibitor
  • the immunoproteasome inhibitor has a structure of or a pharmaceutically acceptable salt thereof.
  • the immunoproteasome inhibitor is administered in an amount of 1 - 300 mg per day. In various cases, the immunoproteasome inhibitor is administered in an amount of 40-120 mg per day. In various cases, the immunoproteasome inhibitor is administered orally, subcutaneously, topically, or intravenously, preferably subcutaneously. In various cases, the immunoproteasome inhibitor is administered once every 7 to 15 days, preferably once every 7 days.
  • the immunosuppressive agent comprises a corticosteriod, an anti-miotic agent, a cytokine antagonist, a B-cell depleting agent, a nonsteriodal antiinflammatory agent, or an antimalarial agent.
  • the immunosuppressive agent comprises one or more of aspirin, prednisone, methylprednisolone, sulfasalazine, leflunomide, hydroxychloroquine, belimumab, mycophenolate mofetil, mycophenolic acid, azathioprine, rituximab, o gearlumab, entanercept, adalimumab, tocilizumab, tofacitinib, baracitinib, cyclosporine, cyclophosphamide, and tacrolimus.
  • the immunosuppressive agent is administered orally, subcutaneously, topically, or intravenously.
  • the immunosuppressive agent comprises mycophenolate mofetil, mycophenolic acid, or a pharmaceutically acceptable salt thereof.
  • the mycophenolate mofetil, or pharmaceutically acceptable salt thereof can be administered in an amount of 0.5-3 g per day, based upon mycophenolate mofetil weight, or the
  • mycophenolic acid, or pharmaceutically acceptable slat thereof is administered in an amount of 700 mg to 1500 mg per day, based upon mycophenolic acid weight.
  • mycophenolate mofetil, mycophenolic acid, or a pharmaceutically acceptable salt thereof can be administerd once per day or twice per day.
  • the immunosuppressive agent is hydroxychloroquine, azathioprine, or cyclophosphamide, or a pharmaceutically acceptable salt thereof.
  • the hydroxychloroquine, or pharmaceutically acceptable salt thereof is administered in an amount of 150 to 325 mg per day, based upon hydroxychloroquine weight.
  • the azathioprine, or pharmaceutically acceptable salt thereof is administered in an amount of 1 to 4 mg/kg per day, based upon azathioprine weight.
  • the immunosuppressive agent is hydroxychloroquine, azathioprine, or cyclophosphamide, or a pharmaceutically acceptable salt thereof.
  • the hydroxychloroquine, or pharmaceutically acceptable salt thereof is administered in an amount of 150 to 325 mg per day, based upon hydroxychloroquine weight.
  • the azathioprine, or pharmaceutically acceptable salt thereof is administered in an amount of 1 to 4 mg/kg per day, based upon azathioprine weight.
  • cyclophosphamide or pharmaceutically acceptable salt thereof, is administered in an amount of 500 to 1000 mg/m 2 every two to four weeks, based upon cyclophosphamide weight.
  • Figure 1 shows the total proteinuria scores for mice given vehicle (circle), 5 mg/kg KZR-616 subcutaneously once weekly (square), 30 mg/kg mycophenolate mofetil (MMF) orally once daily (up triangle), or 5 mg/kg KZR-616 subcutaneously once weekly and 30 mg/kg orally MMF once daily (down triangle) over 25-35 weeks.
  • the top right figure shows the prevention of severe proteinuria of these therapies and the bottom left shows mouse survival over 24-36 weeks when given these therapies.
  • [001 1] Provided herein are methods of treating a subject suffering from an autoimmune disease comprising administering a combination therapy of an immunoproteasome inhibitor and an immunosuppressive agent in an amount sufficient to treat the autoimmune disease.
  • the immunoproteasome inhibitor and/or the immunosuppressive agent may be present as a pharmaceutically acceptable salt thereof.
  • pharmaceutically acceptable salt refers to the relatively non-toxic, inorganic or organic acid addition salt of a compound provided herein. These salts can be prepared in situ during the final isolation and purification of a compound provided herein, or by separately reacting the compound in its free base form with a suitable organic or inorganic acid, and isolating the salt thus formed.
  • Representative salts include the hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, valerate, oleate, palmitate, stearate, laurate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate, lactobionate, laurylsulphonate salts, and amino acid salts, and the like.
  • sulfate bisulfate
  • phosphate nitrate
  • acetate valerate
  • oleate palmitate
  • stearate laurate
  • benzoate lactate
  • phosphate tosylate
  • citrate maleate
  • fumarate succinate
  • tartrate naphthylate
  • mesylate glucoheptonate
  • lactobionate lactobionate
  • laurylsulphonate salts
  • the immunoproteasome inhibitor and the immunosuppressive agent can be administered at the same time or separately. In some cases when they are administered at the same time, the two agents are co-formulated. In cases when they are administered separately, the immunosuppressive agent is administered before the immunoproteasome inhibitor. In other cases when they are administered separately, the immunosuppressive agent is administered after the immunoproteasome inhibitor.
  • the methods disclosed herein can result in a decrease in proteinuria or urine protein to creatinine ratio compared to either (a) a subject not administered the
  • the subject exhibits a decrease in the urine protein to creatinine ratio of at least 50% compared to the urine protein to creatinine ratio of the subject prior to administration of the immunoproteasome inhibitor and the immunosuppressive agent, in some cases, the subject exhibits a decrease in the urine protein to creatinine ratio of at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80% , or at least 85% compared to the urine protein to creatinine ratio of the subject prior to administration of the immunoproteasome inhibitor and the immunosuppressive agent. In some cases, the subject exhibits a urine protein to creatinine ratio of 0.5 or less after administration of the
  • the ratio is 0.4 or less, 0.35 or less, 0.3 or less, 0.3 or less, 0.25 or less, 0.2 or less, 0.15 or less, or 0.1 or less.
  • autoimmune disease is a disease or disorder arising from and directed against an individual's own tissues.
  • autoimmune diseases include, but are not limited to, inflammatory responses such as inflammatory skin diseases including psoriasis and dermatitis (e.g., atopic dermatitis); systemic scleroderma and sclerosis; responses associated with inflammatory bowel disease (such as Crohn's disease and ulcerative colitis); respiratory distress syndrome (including adult respiratory distress syndrome(ARDS));
  • dermatitis dermatitis
  • meningitis encephalitis
  • uveitis uveitis
  • colitis glomerulonephritis
  • allergic conditions such as eczema and asthma and other conditions involving infiltration of T cells and chronic inflammatory responses
  • atherosclerosis leukocyte adhesion deficiency
  • rheumatoid arthritis systemic lupus erythematosus (SLE)
  • diabetes mellitus e.g., Type I diabetes mellitus or insulin dependent diabetes mellitus
  • multiple sclerosis Reynaud's syndrome
  • autoimmune thyroiditis allergic encephalomyelitis
  • Sjorgen's syndrome juvenile onset diabetes
  • pernicious anemia Additional anemia
  • CNS central nervous system
  • diseases involving leukocyte diapedesis central nervous system (CNS) inflammatory disorder; multiple organ injury syndrome; hemolytic anemia (including, but not limited to cryoglobinemia or Coombs positive anemia); myasthenia gravis; antigen-antibody complex mediated diseases; anti-glomerular basement membrane disease; antiphospholipid syndrome; allergic neuritis; Graves' disease; Lambert-Eaton myasthenic syndrome;
  • the autoimmune disease is systemic lupus erythematosus or lupus nephritis. In some cases, the autoimmune disease is systemic vasculitis or idiopathic inflammatory myopathy.
  • SLE Systemic lupus erythematosus
  • SLE affects young adults, occurs more frequently in females than males (9:1 ratio), and is more common in African American, African Caribbean, Hispanic, and Asian populations (approximately 200 cases per 100,000) than in Caucasians (approximately 40 cases per 100,000). It is estimated that there are approximately 250,000 patients with SLE in the US (Feldman et al., 2013; Helmick et al., 2008).
  • Clinical manifestations range from relatively mild skin rashes and arthritis to glomerulonephritis, antibody mediated hemolytic anemia and thrombocytopenia, vasculitis, cardiac disease, and central nervous system disorders including seizures, psychosis, and cerebral vascular accidents (Wallace, 2015) (Tsokos, 201 1 ).
  • the accurate diagnosis of SLE can be difficult because the clinical manifestations vary considerably between patients, and the individual signs and symptoms of SLE can have multiple etiologies.
  • Classification criteria have been developed by the American College of Rheumatology (ACR) (Hochberg, 1997; Tsokos, 201 1 ).
  • SLE is thought to be the result of dysfunction of multiple components of the immune system, including defective clearance of apoptotic cellular components, a break in T-cell tolerance induction, and generation of antibodies against nuclear antigens (ANA) such as anti-double stranded DNA (anti-dsDNA) (Kaul et al., 2016).
  • ANA nuclear antigens
  • antigens to create antigen antibody (Ag-Ab) complexes, which are deposited in various tissues and initiate inflammatory reactions via complement activation (e.g., arthritis and glomerulonephritis) or Type II hypersensitivity reactions in which antibodies directly target host cells and activate immune effector mechanisms that lead to phagocytosis (e.g., hemolytic anemia or immune thrombocytopenia).
  • complement activation e.g., arthritis and glomerulonephritis
  • Type II hypersensitivity reactions in which antibodies directly target host cells and activate immune effector mechanisms that lead to phagocytosis (e.g., hemolytic anemia or immune
  • LN Lupus nephritis
  • LN LN lN
  • LN results when Ag-Ab complexes (predominantly DNA-anti-DNA) are deposited in the glomerular mesangium and glomerular basement membrane and activate serum complement. The resulting inflammatory response causes damage to the glomerular epithelium with loss of function. It is often accompanied by mesangial proliferation and subsequent sclerosis of the glomeruli. Histopathologically, LN can take many forms, ranging from a normal glomerular architecture with Ag-Ab complexes identified by
  • ISN/RPS Nephrology/Renal Pathology Society
  • CRR complete renal response
  • the proteasome has been posited as a target for drug development in chronic inflammatory conditions and autoimmune disorders (Elliott, Zollner, & Boehncke, 2003).
  • Bortezomib blocks cytokine release from immune effector cells and has demonstrated antiinflammatory activity in several animal models of autoimmune disorders including rheumatoid arthritis (RA) (Palombella et al., 1998) and SLE (Neubert et al., 2008). More recently, bortezomib was shown to have clinical activity in patients with refractory SLE and LN who had failed standard immunosuppressive therapies (Alexander et al., 2015; de Groot et al., 2015; Zhang et al., 2017).
  • bortezomib is associated with a dose limiting side effect of peripheral neuropathy, likely caused by off-target inhibition of the serine protease HtrA2 in neurons (Arastu-Kapur et al., 201 1 ).
  • Peripheral neuropathy is not induced by the peptide ketoepoxide proteasome inhibitor, carfilzomib (Arastu-Kapur et al., 201 1 ; Dimopoulos et al., 2016).
  • ONX 0914 is a tripeptide ketoepoxide analog of carfilzomib and selectively inhibits the immunoproteasome in vitro and upon administration to mice.
  • ONX 0914 exposure inhibited cytokine production in immune effector cells, reduced the number and activity of inflammatory T-cell subsets such as Th1 and Th17, increased the number of regulatory T-cells (Treg), and blocked autoantibody formation (lchikawa et al., 2012; Kalim, Basler, Kirk, & Groettrup, 2012), (Muchamuel et al., 2009).
  • ONX 0914 was found to prevent joint- specific inflammation, reduce cytokine production, and ameliorate joint damage at doses one tenth of the maximum tolerated dose (MTD) (Muchamuel et al., 2009).
  • ONX 0914 Treatment of mice with ONX 0914 did not reduce the number of splenic lymphocytes or impair viral clearance in multiple infection models (Muchamuel et al., 2009; Mundt, Engelhardt, Kirk, Groettrup, & Basler, 2016). In addition, ONX 0914 was shown to be therapeutically active in mouse models of multiple sclerosis and SLE, in which it demonstrated equivalent activity but better tolerability than bortezomib (Basler et al., 2014; lchikawa et al., 2012).
  • Immunoproteasome inhibitors contemplated in the disclosed methods include those as described in WO 07/149512 (e.g., ONX 0914), WO 96/13266 (e.g., bortezomib VELCADE®), and WO 14/152134, the disclosures of which are each incorporated by reference in their entirety.
  • Some specific immunoproteasome inhibitors contemplated include those having a structure of formula (I): wherein
  • E is N orCH
  • immunoproteasome inhibitor having a structure
  • This compound is alternatively referred to throughout as KZR-616.
  • KZR-616 induces potent and selective inhibition of the immunoproteasome in human cells in vitro and potent and selective inhibition in blood and tissues when administered to rats and monkeys. KZR-616 did not inhibit any non-proteasomal targets in a broad diversity panel of biochemical assays that included 1 10 receptor/ligand and enzyme assays.
  • KZR-616 In vitro, KZR-616 demonstrates potent and selective inhibition (relative to ⁇ 5) of the LMP7 subunit of the immunoproteasome and can target multiple subunits of the
  • KZR-616 blocks cytokine production across multiple immune cell types, reduces the activity of inflammatory T-helper cell subsets, increases the number of regulatory T-cells, and blocks plasma cell formation and autoantibody production.
  • KZR-616 can be administered once weekly (e.g., every seven days) up to once bimonthly (e.g., every 15 days), e.g., once every 7 days, once every 8 days, once every 9 days, once every 10 days, once every 1 1 days, once every 12 days, once every 13 days, once every 14 days, or once every 15 days.
  • the dose of KZR-616 can be 1 to 300 mg/day. If the dose frequency is less than once daily (e.g., every 7 days), the total dose given to the subject will be multiplied by that amount e.g., 7 to 2100 mg given once every 7 days.
  • the KZR-616 dose is 40 to 120 mg/day (which can also be given in less than daily dosing frequency).
  • the daily dose of KZR-616 does not indicate that the amount is given daily, but could be combined with other daily doses to be administered to the subject in less frequent doses.
  • the immunoproteasome inhibitor can be administered orally, subcutaneously, topically, or intravenously. In some specific cases, the immunoproteasome inhibitor is administered subcutaneously.
  • immunosuppressive agent refers to a substance that acts to suppress or mask the immune system of the subject being treated herein.
  • substances that suppress cytokine production, down-regulate or suppress self-antigen expression, or mask the MHC antigens are contemplated.
  • agents include corticosteriods, anti-miotic agents, cytokine antagonists, B-cell depleting agents, nonsteriodal anti-inflammatory agents, and an antimalarial agents.
  • Immunosuppressive agents contemplated include 5-amino-6-aryl-5-substituted pyrimidines (see U.S. Pat. No. 4,665,077); nonsteroidal anti-inflammatory drugs (NSAIDs); ganciclovir, tacrolimus, glucocorticoids such as Cortisol or aldosterone, anti-inflammatory agents such as a cyclooxygenase inhibitor, a 5- lipoxygenase inhibitor, or a leukotriene receptor antagonist; purine antagonists such as azathioprine or mycophenolate mofetil (MMF); alkylating agents such as cyclophosphamide; bromocryptine; danazol; dapsone; glutaraldehyde (which masks the MHC antigens, as described in U.S.
  • NSAIDs nonsteroidal anti-inflammatory drugs
  • ganciclovir tacrolimus
  • glucocorticoids such as Cortisol or aldosterone
  • anti-idiotypic antibodies for MHC antigens and MHC fragments include cyclosporin A; steroids such as corticosteroids or glucocorticosteroids or glucocorticoid analogs, e.g., prednisone, methylprednisolone, and dexamethasone; dihydrofolate reductase inhibitors such as methotrexate (oral or subcutaneous); hydroxycloroquine; sulfasalazine; leflunomide; cytokine or cytokine receptor antagonists including anti-interferon-alpha, -beta, or -gamma antibodies, anti-tumor necrosis factor-alpha antibodies (infliximab or adalimumab), anti-TNF-alpha immunoahesin (etanercept), anti-tumor necrosis factor-beta antibodies, anti-interleukin-2 antibodies and anti-IL-2
  • T-cell receptor Cohen et al., U.S. Pat. No. 5,1 14,721
  • T-cell receptor fragments Offner et al., Science, 251 : 430-432 (1991 ); WO 90/1 1294; laneway, Nature, 341 : 482 (1989); and WO 91/01 133
  • T cell receptor antibodies EP 340,109
  • the immunosuppressive agent is one or more of aspirin, prednisone, methylprednisolone, sulfasalazine, leflunomide, hydroxychloroquine, belimumab, mycophenolate mofetil, mycophenolic acid, azathioprine, rituximab, o gearlumab, entanercept, adalimumab, tocilizumab, tofacitinib, baracitinib, cyclosporine, cyclophosphamide, and tacrolimus.
  • the immunosuppressive agent comprises mycophenolate mofetil, mycophenolic acid, or a pharmaceutically acceptable salt thereof.
  • the mycophenolate mofetil, mycophenolic acid, or a pharmaceutically acceptable salt thereof can be administered in an amount of 500 mg to 3 g per day or 700 mg to 1500 mg, based upon the weight of the mycophenolate mofetil or mycophenolic acid. In some cases the
  • immunosuppressive agent is administered once or twice daily.
  • the immunosuppressive agent comprises hydroxychloroquine, azathioprine, or cyclophosphamide, or a pharmaceutically acceptable salt thereof.
  • the hydroxychloroquine, or pharmaceutically acceptable salt thereof can be administered in an amount of 150 to 325 mg per day, based upon hydroxychloroquine weight.
  • azathioprine or pharmaceutically acceptable salt thereof
  • the cyclophosphamide, or pharmaceutically acceptable salt thereof can be administered in an amount of 500 to 1000 mg/m 2 every two to four weeks, based upon cyclophosphamide weight.
  • the immunosuppressive agent can be administered orally, subcutaneously, topically, or intravenously.
  • NZB/W F1 mice were purchased from Jackson Laboratories. All mice were housed in the animal facility at Kezar Life Sciences. All experiment protocols were reviewed and approved by the Kezar Committee on Animal Resources. NZB/WF1 mice with established nephritis (24 weeks of age with duratble proteinuria >1 + proteinuria) were treated with vehicle alone, 2.5 mg/kg KZR-616 SC QW, 30 mg/kg QDx7 PO MMF or the combination of 2.5 mg/kg KZR-616 SC QW KZR-616 and 30 mg/kg QDx7 PO MMF. Proteinuria was monitored weekly once with urine dipsticks (Uristix by Bayer) and survival was observed.
  • mice were administered vehicle alone, 2.5 mg/kg KZR-616 SC QW, 30 mg/kg QDx7 PO MMF or the combination of KZR-616 and MMF.
  • 2.5 mg/kg KZR-616 or 30 mg/kg MMF treatment significantly reduced the level of proteinuria and increased survival.
  • KZR-616 in combination with MMF showed significantly greater disease inhibition (as measured by proteinuria) and prolonged survival compared to vehicle or KZR-616 and MMF treatment alone.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne des procédés de traitement de maladies auto-immunes comprenant l'administration à un sujet souffrant de celles-ci d'un inhibiteur d'immunoprotéasome et d'un agent immunosuppresseur.
EP18765279.7A 2017-08-23 2018-08-23 Inhibiteurs d'immunoprotéasome et agent immunosuppresseur dans le traitement de troubles auto-immuns Pending EP3672586A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762549020P 2017-08-23 2017-08-23
PCT/US2018/047622 WO2019040680A1 (fr) 2017-08-23 2018-08-23 Inhibiteurs d'immunoprotéasome et agent immunosuppresseur dans le traitement de troubles auto-immuns

Publications (1)

Publication Number Publication Date
EP3672586A1 true EP3672586A1 (fr) 2020-07-01

Family

ID=63490724

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18765279.7A Pending EP3672586A1 (fr) 2017-08-23 2018-08-23 Inhibiteurs d'immunoprotéasome et agent immunosuppresseur dans le traitement de troubles auto-immuns

Country Status (5)

Country Link
US (1) US20210128667A1 (fr)
EP (1) EP3672586A1 (fr)
JP (1) JP7289828B2 (fr)
CN (2) CN117338932A (fr)
WO (1) WO2019040680A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024140736A1 (fr) * 2022-12-27 2024-07-04 上海美悦生物科技发展有限公司 Composé tripeptide époxy cétone, composition pharmaceutique, son procédé de préparation et son utilisation
GB202312279D0 (en) * 2023-08-10 2023-09-27 Univ Leiden New compounds and uses

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL47062A (en) 1975-04-10 1979-07-25 Yeda Res & Dev Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde
US4665077A (en) 1979-03-19 1987-05-12 The Upjohn Company Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds
IL85746A (en) 1988-03-15 1994-05-30 Yeda Res & Dev Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases
FI891226L (fi) 1988-04-28 1989-10-29 Univ Leland Stanford Junior Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom.
WO1990008187A1 (fr) 1989-01-19 1990-07-26 Dana Farber Cancer Institute Proteine cd2 soluble a deux domaines
EP0463101B2 (fr) 1989-03-21 2003-03-19 The Immune Response Corporation Vaccination et procedes contre des maladies resultant des reponses pathogeniques par des populations de cellules t specifiques
NZ234586A (en) 1989-07-19 1993-02-25 Arthur Allen Vandenbark Peptide of a t-cell receptor capable of inducing protection from immune-related disease
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US7589066B2 (en) * 2005-03-11 2009-09-15 The University Of North Carolina At Chapel Hill Potent and specific immunoproteasome inhibitors
US20080279848A1 (en) * 2006-03-16 2008-11-13 Genentech, Inc. Methods of treating lupus using CD4 antibodies
SI2041158T1 (sl) 2006-06-19 2013-09-30 Onyx Therapeutics, Inc. Peptidni epoksiketoni za inhibicijo proteasomov
TW201309303A (zh) * 2011-03-03 2013-03-01 Cephalon Inc 用於治療狼瘡的蛋白酶體抑制劑
CA2904085C (fr) * 2013-03-14 2021-07-06 Onyx Therapeutics, Inc. Inhibiteurs de dipeptide et de tripeptide epoxy cetone proteases
AR095426A1 (es) * 2013-03-14 2015-10-14 Onyx Therapeutics Inc Inhibidores tripeptídicos de la epoxicetona proteasa
KR20170066506A (ko) * 2014-10-01 2017-06-14 메르크 파텐트 게엠베하 보론산 유도체

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
H. TRAVIS ICHIKAWA ET AL: "Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells", ARTHRITIS & RHEUMATISM, vol. 64, no. 2, 1 February 2012 (2012-02-01), US, pages 493 - 503, XP055466333, ISSN: 0004-3591, DOI: 10.1002/art.33333 *

Also Published As

Publication number Publication date
WO2019040680A8 (fr) 2020-02-27
CN117338932A (zh) 2024-01-05
JP2020531494A (ja) 2020-11-05
JP7289828B2 (ja) 2023-06-12
US20210128667A1 (en) 2021-05-06
WO2019040680A1 (fr) 2019-02-28
CN111601597A (zh) 2020-08-28
CN111601597B (zh) 2023-10-13

Similar Documents

Publication Publication Date Title
KR102220006B1 (ko) 자가면역 - 관련 또는 염증성 장애를 치료하기 위한 저용량 ｉｌ­２ 의 용도
Janssen et al. Regulation of activation-induced cell death of mature T-lymphocyte populations
JP6364352B2 (ja) 部分的ｍｈｃコンストラクト及びその使用方法
US20210128667A1 (en) Immunoproteasome inhibitors and immunosuppressive agent in the treatment of autoimmune disorders
JP2012001547A (ja) 自己免疫疾患の治療のための方法および組成物
CN106061502B (zh) 基于脂质体的免疫疗法
Llop-Guevara et al. Simultaneous inhibition of JAK and SYK kinases ameliorates chronic and destructive arthritis in mice
WO2000020010A1 (fr) Administration en jours alternes de copolymer 1 destine au traitement de maladies autoimmunes
JP3665342B2 (ja) 新規ペプチド
CA2584971A1 (fr) Methodes d'inhibition des cellules nkt
Pavlovic et al. Intravenous immunoglobulins exposed to heme (heme IVIG) are more efficient than IVIG in attenuating autoimmune diabetes
Kaplan et al. Therapeutic benefit of treatment with anti-thymocyte globulin and latent TGF-β1 in the MRL/lpr lupus mouse model
US20200276204A1 (en) Combination therapy for immunological diseases
RU2764216C1 (ru) Способ лечения гломерулонефритов с нефротическим синдромом рецидивирующего течения
Lum et al. Hematopoietic cell transplantation in monogenic autoimmune diseases
AU2740900A (en) Method of treating demyelinating inflammatory disease using ccr1 antagonists
Brand et al. A quick and painless reminder: the pharmacotherapy of rheumatoid arthritis in primary practice
US20060183664A1 (en) Pharmaceutical composition for delayed hypersensitivity
Fajar et al. B Cell-Activating Factor (BAFF) and Ubiquitin Enzyme A20 as Functional Proteins in Targeted Therapy on Patients with Systemic Lupus Erythematosus
Iorember et al. Rapidly progressive glomerulonephritis and vasculitis
Manieri et al. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): A case with adverse reaction to three drugs alternately administered
Sabry et al. SINGLE-CENTER EXPERIENCE WITH CYCLOSPORINE FOR TREATMENT OF IDIOPATHIC MINIMAL CHANGE NEPHROTIC SYN-DROME IN CHILDREN
Ponticelli et al. Minimal change disease
US20190352341A1 (en) Modified peptides and their use for treating systemic lupus erythematosus
Unni et al. DRUGS IN PEDIATRIC RHEUMATOLOGY

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200228

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20230919